GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » Cyclically Adjusted FCF per Share

Supernus Pharmaceuticals (Supernus Pharmaceuticals) Cyclically Adjusted FCF per Share : $1.97 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2023 was $0.814. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.97 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Supernus Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 32.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-04-27), Supernus Pharmaceuticals's current stock price is $30.07. Supernus Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $1.97. Supernus Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 15.26.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Supernus Pharmaceuticals was 303.70. The lowest was 12.67. And the median was 25.44.


Supernus Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.15 -0.80 0.97 1.49 1.97

Supernus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.49 1.66 1.71 1.86 1.97

Competitive Comparison of Supernus Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Supernus Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Supernus Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.814/129.4194*129.4194
=0.814

Current CPI (Dec. 2023) = 129.4194.

Supernus Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.471 99.695 -0.611
201406 -0.167 100.560 -0.215
201409 -0.112 100.428 -0.144
201412 0.143 99.070 0.187
201503 -0.010 99.621 -0.013
201506 0.237 100.684 0.305
201509 0.028 100.392 0.036
201512 0.370 99.792 0.480
201603 -0.067 100.470 -0.086
201606 0.312 101.688 0.397
201609 0.536 101.861 0.681
201612 0.474 101.863 0.602
201703 0.247 102.862 0.311
201706 0.477 103.349 0.597
201709 0.719 104.136 0.894
201712 0.665 104.011 0.827
201803 0.500 105.290 0.615
201806 0.115 106.317 0.140
201809 1.148 106.507 1.395
201812 0.605 105.998 0.739
201903 0.607 107.251 0.732
201906 0.532 108.070 0.637
201909 0.691 108.329 0.826
201912 0.805 108.420 0.961
202003 0.119 108.902 0.141
202006 1.704 108.767 2.028
202009 0.099 109.815 0.117
202012 0.588 109.897 0.692
202103 0.632 111.754 0.732
202106 0.846 114.631 0.955
202109 -0.076 115.734 -0.085
202112 0.894 117.630 0.984
202203 0.056 121.301 0.060
202206 1.168 125.017 1.209
202209 0.249 125.227 0.257
202212 0.444 125.222 0.459
202303 0.782 127.348 0.795
202306 -0.349 128.729 -0.351
202309 0.654 129.860 0.652
202312 0.814 129.419 0.814

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Supernus Pharmaceuticals  (NAS:SUPN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Supernus Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=30.07/1.97
=15.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Supernus Pharmaceuticals was 303.70. The lowest was 12.67. And the median was 25.44.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Supernus Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Executives
Tami Tillotson Martin officer: Sr. V.P., Regulatory Affairs C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii director 1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson director 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Frank Mottola officer: Sr VP, Quality, GMP Oper. & IT 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Jack A. Khattar director, officer: President, CEO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt officer: Sr. VP of IP, CSO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Timothy C Dec officer: Senior Vice-President & CFO C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jonathan Rubin officer: SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Schwabe Stefan K.f. officer: Executive Vice President R&D C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick officer: VP, Chief Financial Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly officer: Executive Vice-President & CFO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn officer: Sr. VP of Sales C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
M James Barrett director, 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202